←
Grainne O'Kane973 posts
Grainne O'Kane avatar✓

Grainne O'Kane ✓

@graokane

Medical Oncologist; clinical and translational researcher pancreatic and hepatobiliary cancers. Views are my own 🇮🇪🇨🇦

◷ Joined August 2013▧ 185 Photos and videos
Teresa Macarulla avatar
⟳ Grainne O'Kane retweeted
Teresa Macarulla@MacarullaTeresa·Nov 16

The European Commission has approved daraxonrasib (RASONQUE®), the first broad RAS-targeted therapy for metastatic pancreatic cancer An important milestone for patients with pancreatic adenocarcinoma 💜 A promising step forward! #PancreaticCancer @RevMedicines

LARVOL avatar
⟳ Grainne O'Kane retweeted
LARVOL@Larvol·Oct 29

@myESMO 2026: Top trending GI cancer oncologists on 𝕏 Explore #ESMO26 insights here: clin.larvol.com/conference/a… #LARVOL #ESMO2026 #CancerResearch #CancerData #Oncology #OncologyInsights #MedicalOncology #ClinicalTrials #GICancer #GastrointestinalCancer #GICSM #ColorectalCancer #GastricCancer #LiverCancer #PancreaticCancer #ClinicalOncology | @Erman_Akkus | @GIMedOnc | @DraMartinezLago | @GillSharlene | @DaisukeKotani | @ilyassahinMD | @TapiaJC1 | @ArndtVogel | @Aiims1742 | @YannickBuccella | @DrAngelaLamarca | @CathyEngMD | @pashtoonkasi | @graokane | @UGrewalMD

Post attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 26

OPTIMUM rand ph2 adv #BTC ➡️dx control on plat- olaparib v olaparib/durva ➡️somatic/ germline DDR but wide range genes ➡️❗️BRCA1/2/PALB2 ~30% (⬆️Olap arm) ❎no diff 6mth PFS ❎1yr OS rate 64 v76% ❗️we must define true HRD in trials & understand TME @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 26

Final analysis LEAP012 unresectable #HCC TACE +Len/Pembro v TACE ➡️mPFS 14.6 v 10.2 HR 0.7 ➡️ORR 71 v 49% by mRECIST ❎mOS 40.4 v 40.6; ~1/3 in both subsequent tx ❎much higher gd3/4 TRAEs 71%v31% ➡️❗️1/3 BCLCA ➡️Role combo unclear consistent -ve OS @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 26

🔥Ph2 Peri-operative RASi (HRS-4642, G12D)+ GnP +/-adebrelimab (PD-L1) ➡️two cohorts n=60 #PDAC ➡️safety- mainly haem, none precluded surgery ➡️ORR 63% & 87%;MPR in 17% ➡️R0 resection rate 100% ✅6 mth EFS rate 87% & 96% ➡️100% ⬇️CA19.9; OS pending @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 26

INCB161734 KRASG12D (ON/OFF) + GnP or mFFX; updated ph1, n=53 ➡️mostly GI toxicity,dose intensity 85% with GnP & 77%mFFX ✅ORR 69%, DCR 96% GnP ✅ORR 89%, DCR 100% mFFX ➡️6 mth PFS rates 80% & 90% ⭐️impressive & can combine mFFX ✅DAWN-303 ph3 ongoing @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 25

🔥HARMONi-GI1 ph3 advanced #BTC ➡️ivonescimab/GC v durva/GC mFU 14.3mths; China only & interim ✅ iCCA 58% ORR 53.8v32.5%; mPFS 8.4 v 5.8mths ✅mOS 14.9 v12.1mths HR0.75 ➡️AE rate high in both Control arm OS represents❗️VEGF in BTC ⭐️ looks promising @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 25

GFH276 pan-RAS (ON) molecular glue ➡️ph1/1b data; n=73 PDAC ,5-320mg ➡️no . prior lines tx =2 ➡️ORR 41% in #PDAC, @ 40-160mg, small nos with prior RASi ➡️Rash most common AE As many trials move quickly to 1st line, how will we sequence?? @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 24

🔥Promising #HCC BGB-B2033 ➡️GPC3 x 4-1BB bispecific ph1/2 more mature data ➡️dose escalation/optimisation activity across all: 2/3rd >2 prior lines ORR ~36% ➡️450mg selected R2PD; very favourable toxicity ➡️Phase 3 GroundBBreaker 301 due to open @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 24

Much anticipated ACTICCA-1 ➡️adj cis/gem v cape #BTC ➡️mod ITT n=591 ➡️no diff in DFS at 24mth 52% v 44% RMST at 3 yrs ⬆️DFS by 2.6mth ➡️28% iCCA -no maj subgroup diff ➡️mOS 58.1 v 48.2 p=0.1 ❎No change to std ?an option, NB need as backbone 1st line! @myESMO @OncoAlert #ESMO26

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 24

Paclitaxel +\-tovecimig: COMPANION-002 ph2/3 ➡️prev treated #BTC wo actionable alterations ➡️ORR 17.1 v5.3%; DCR 62 v 37% ➡️mPFS 4.7 v 2.6mths - benefits seen at PFS2 noting crossover ➡️OS not sig but nb crossover @myESMO #ESMO26 @OncoAlert

Post attachmentPost attachmentPost attachmentPost attachment
Grainne O'Kane avatar
Grainne O'Kane@graokane·Oct 23

MASTERPLAN randomised ph2 ➡️chemo(90% mFFX) +\-SBRT localised #PDAC ➡️included potentially operable high risk /BR &LAPC not operable ➡️primary endpoint 12mth LRR :20% v 52% ➡️more R0 resections with SBRT ➡️mPFS 11.9 v6.3mth; mOS 22 v 14mth @myesmo #ESMO26 @oncoalert

Post attachmentPost attachmentPost attachmentPost attachment